News Search Results
Feb 03, 2026, 04:31 ET Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPα Monoclonal Antibody for Advanced Solid Tumors
and NANJING, China, Feb. 3, 2026 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global, clinical-stage biotechnology company developing innovative antibody-based therapeutics, today announced that the first patient has been dosed in a Phase 1a/1b Investigator-Initiated
More news about: Biosion, Inc.
Feb 03, 2026, 00:00 ET UAE Partners with Colossal Biosciences to Protect Biodiversity and Champion the Future of Life on Earth
This collaboration represents a major step forward in advancing global conservation and biotechnology, supporting biodiversity and species preservation worldwide. It underscores both the UAE's and Colossal's commitment to advancing science, sustainability,
More news about: Colossal Biosciences
Feb 02, 2026, 16:00 ET CREATE Medicines Demonstrates Complete B Cell Depletion and Repeatable Dosing in Non-human Primates with In Vivo CAR-T Platform
CAMBRIDGE, Mass., Feb. 2, 2026 /PRNewswire/ -- CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo CAR therapy, today announced new detailed data demonstrating complete B cell depletion in NHPs using its proprietary
More news about: CREATE Medicines, Inc.
Feb 02, 2026, 12:53 ET Virtual Science AI launches the life science industry's first medical congress AI solution for real-time event conversational intelligence
(SaaS) solution for the life-science and healthcare sectors. The company partners with most top 20 leading pharmaceutical companies and numerous biotechnology firms. Virtual Science AI's proprietary medical intelligence platform solutions transform complex scientific data into actionable intelligence,
More news about: Virtual Science AI Ltd
Feb 02, 2026, 10:01 ET Laboratory Equipment Services Market worth $35.4 billion by 2030 | MarketsandMarkets™
integration, tight calibration tolerances, and accuracy and reproducibility requirements, especially in regulated industries such as pharmaceuticals, biotechnology, and clinical diagnostics. Because of this complexity, laboratories are choosing to outsource maintenance, calibration, repair, and testing, leading
More news about: MarketsandMarkets
Feb 02, 2026, 10:00 ET ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging
drawing keen interest from attendees.About ACROBiosystems GroupACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models.
More news about: ACROBiosystems
Feb 02, 2026, 09:00 ET Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Adopted Names (USAN) Council approved "liraltagene
More news about: Anixa Biosciences, Inc.
Feb 02, 2026, 08:30 ET Lupin Launches Dasatinib Tablets in the United States
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Feb 02, 2026, 08:25 ET Mwyngil Therapeutics Announces Updates on NLRP3 Portfolio
cardiometabolic conditions, with first-in-human studies planned for 2027.About Mwyngil TherapeuticsMwyngil Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies for neuroinflammatory, immunometabolic, and inflammatory diseases.
More news about: Mwyngil Therapeutics
Feb 02, 2026, 08:09 ET Santé Ventures Raises $330 Million for Fifth Fund to Advance Breakthrough Healthcare Innovation
fund with $330 million in committed capital, exceeding its $300 million target. Fund V will continue the firm's focus on investing in innovative biotechnology, medical technology, and digitally enabled healthcare companies addressing significant unmet medical needs. This marks Santé's largest fund to date
More news about: Santé Ventures
Feb 02, 2026, 07:00 ET SanegeneBio Announces RNAi Global Licensing Collaboration with Genentech
SUZHOU, China, Feb. 2, 2026 /PRNewswire/ -- SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global licensing agreement with Genentech, a member of the Roche Group, to advance
More news about: SanegeneBio
Feb 02, 2026, 05:08 ET Aphranel lanza la estrategia de marca "La poética del tiempo" en IMCAS París
2026 en París, Aphranel, marca china de medicina estética regenerativa especializada en inyectables de CaHA, bajo la dirección de SHANGHAI MOYANG BIOTECHNOLOGY, presentó su estrategia global de marca, "La poética del tiempo". El lanzamiento marcó la presentación de la filosofía estética a largo plazo de
More news about: SHANGHAI MOYANG BIOTECHNOLOGY CO., LTD
Feb 02, 2026, 04:20 ET IoT in Healthcare Market to Reach US$594.5 Bn by 2035 at 23.85% CAGR | Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Feb 01, 2026, 01:38 ET Aphranel stellt auf der IMCAS Paris die Markenstrategie "The Poetics of Time" vor und definiert den langfristigen Wert der medizinischen Ästhetik neu
stammende Marke für regenerative medizinische Ästhetik, die sich auf CaHA-Injektionsmittel spezialisiert hat und zum Unternehmen SHANGHAI MOYANG BIOTECHNOLOGY gehört, ihre globale Markenstrategie "The Poetics of Time" vor. Mit der Lancierung stellte Aphranel seine langfristige ästhetische Philosophie
More news about: SHANGHAI MOYANG BIOTECHNOLOGY CO., LTD
Feb 01, 2026, 01:35 ET Aphranel lance sa stratégie de marque "La Poétique du Temps" à IMCAS Paris, redéfinissant ainsi la valeur à long terme de l'esthétique médicale
marque d'esthétique médicale régénérative d'origine chinoise spécialisée dans les injectables CaHA, sous l'égide de la société SHANGHAI MOYANG BIOTECHNOLOGY, a dévoilé sa stratégie de marque globale, "The Poetics of Time." Ce lancement a permis à Aphranel de présenter sa philosophie esthétique
More news about: SHANGHAI MOYANG BIOTECHNOLOGY CO., LTD
Feb 01, 2026, 00:33 ET Aphranel Launches "The Poetics of Time" Brand Strategy at IMCAS Paris, Redefining Long-Term Value in Medical Aesthetics
Congress in Paris, Aphranel, a China-origin regenerative medical aesthetics brand specializing in CaHA injectables, under the company SHANGHAI MOYANG BIOTECHNOLOGY, unveiled its global brand strategy, "The Poetics of Time." The launch marked Aphranel's introduction of its long-term aesthetic philosophy
More news about: SHANGHAI MOYANG BIOTECHNOLOGY CO., LTD
Feb 01, 2026, 00:18 ET Aphranel Launches "The Poetics of Time" Brand Strategy at IMCAS Paris, Redefining Long-Term Value in Medical Aesthetics
Congress in Paris, Aphranel, a China-origin regenerative medical aesthetics brand specializing in CaHA injectables, under the company SHANGHAI MOYANG BIOTECHNOLOGY, unveiled its global brand strategy, "The Poetics of Time." The launch marked Aphranel's introduction of its long-term aesthetic philosophy
More news about: SHANGHAI MOYANG BIOTECHNOLOGY CO., LTD
Jan 31, 2026, 23:36 ET Trace Biosciences Announces FDA IND Clearance for First Nerve-Specific Imaging Agent
PORTLAND, Ore., Jan. 31, 2026 /PRNewswire/ -- Trace Biosciences, Inc., a clinical-stage biotechnology company developing nerve-targeted imaging agents, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational
More news about: Trace Biosciences
Jan 30, 2026, 17:00 ET Origin Agritech Announces Fiscal Year 2025 Results
first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline, including products with glyphosate tolerance and pest resistance (Bt) traits. For further information, please visit the Company's
More news about: Origin Agritech Limited
Jan 30, 2026, 16:10 ET Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
conditions of the stock option agreement covering the grant.About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Jan 30, 2026, 13:04 ET Kos Biotechnology Partners Announces Inaugural Investment, Leads Epikast's Financing Round
currently partners with several global top 10 pharma companies and smaller biotechnology companies as they commercialize their products in the US and Europe.About Kos Biotechnology PartnersKos Biotechnology Partners is a global investment firm founded in 2025 by Dr. Simos Simeonidis
More news about: Kos Biotechnology Partners
Jan 30, 2026, 11:00 ET Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jan 30, 2026, 02:56 ET Aquaporin announces withdrawal of its offering and resolves to initiate insolvency proceedings
company with operations in Denmark (HQ), Singapore, Turkey, the United States, and China. We are committed to rethinking water filtration with biotechnology to solve global water challenges. By combining three disciplines from the world of natural sciences: biology, chemistry, and physics, we have created
More news about: Aquaporin A/S
Jan 30, 2026, 02:54 ET Aquaporin announces withdrawal of its offering and resolves to initiate insolvency proceedings
company with operations in Denmark (HQ), Singapore, Turkey, the United States, and China. We are committed to rethinking water filtration with biotechnology to solve global water challenges. By combining three disciplines from the world of natural sciences: biology, chemistry, and physics, we have created
More news about: Aquaporin A/S
Jan 29, 2026, 17:31 ET Chronic Hepatitis D Market Poised for Significant Growth During the Forecast Period (2025-2034) as Emerging Therapies Drive Optimism | DelveInsight
Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences,
More news about: DelveInsight Business Research, LLP